NCT03129113 (MAVMET) is a Phase 2, PHASE3 clinical trial of Maraviroc in Hepatic Steatosis, sponsored by University College, London.

Who is sponsoring NCT03129113?

NCT03129113 is sponsored by University College, London.

What drugs are being tested in NCT03129113?

Interventions in NCT03129113: Maraviroc, Metformin.

What condition does NCT03129113 study?

NCT03129113 studies Hepatic Steatosis, HIV-1-infection.

Is NCT03129113 still recruiting?

NCT03129113 is currently completed. Last updated 4 November 2021.

Last reviewed 2021-11-04 · How we verify

NCT03129113: MAVMET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

Completed Phase 2, PHASE3 Last updated 4 November 2021

What this trial tests

Phase 2, PHASE3 trial testing Maraviroc in Hepatic Steatosis in 90 participants. Completed in 6 November 2020.

Timeline

1 March 2017

Primary endpoint
5 November 2020

6 November 2020

Quick facts

Lead sponsor	University College, London
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	single
Primary purpose	treatment
Enrollment	90
Start date	1 March 2017
Primary completion	5 November 2020
Estimated completion	6 November 2020
Sites	6 locations across United Kingdom

Drugs / interventions tested

Maraviroc (MARAVIROC) — full drug profile →
Metformin (metformin) — full drug profile →

Conditions studied

Hepatic Steatosis — all drugs for Hepatic Steatosis →
HIV-1-infection — all drugs for HIV-1-infection →

Sponsor

University College, London

Who can join

35 and older, any sex, with Hepatic Steatosis or HIV-1-infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentre, phase IV, randomised, open-label, trial exploring adjunctive maraviroc and/or metformin for liver steatosis over 48 weeks. Sponsored by University College London Coordinated by MRC Clinical Trials Unit at UCL

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease.
Wiering L, Subramanian P, Hammerich L. · · 2023 · cited 39× · PMID 36828280 · DOI 10.1016/j.jcmgh.2023.02.010
New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine.
Xu H, Lin S, Zhou Z, Li D, et al · · 2023 · cited 37× · PMID 37198402 · DOI 10.1038/s41423-023-01032-x
Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages.
Saminathan P, Kevadiya BD, Marker DF, Gendelman HE, et al · · 2019 · cited 5× · PMID 30617749 · DOI 10.1007/s11481-018-09829-8

Verify or expand the search:

Other trials of Maraviroc

Trials testing the same drug.

NCT06853223 — This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction · Phase 2 · recruiting
NCT06805656 — Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals · Phase 2 · not yet recruiting
NCT05470491 — Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll · Phase 1, PHASE2 · recruiting
NCT04435522 — Maraviroc in Patients With Moderate and Severe COVID-19 · Phase 1 · completed
NCT03274804 — Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC · Phase 1 · completed

Other recruiting trials for Hepatic Steatosis

Currently open trials in the same condition.

NCT07481734 — Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) · Phase 2 · recruiting
NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
NCT07192159 — Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD · NA · recruiting
NCT06891365 — Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases · Phase 1 · recruiting
NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting

Other University College, London trials

Trials by the same sponsor.

NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03129113 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University College, London
Last refreshed: 4 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03129113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing